Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy

• Published in: Anticancer research 2017-05, Vol.37 (5), p.2715-2720
• Main Authors: Kanazawa, Yoshikazu, Fujita, Itsuo, Kakinuma, Diasuke, Arai, Hiroki, Matsuno, Kunihiko, Shimoda, Tomohiro, Ko, Kazuhide, Kato, Shunji, Uchida, Eiji
• Format: Article
• Language: English
• Subjects: Aged; Albumins - adverse effects; Albumins - therapeutic use; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel - adverse effects; Paclitaxel - therapeutic use; Stomach Neoplasms - drug therapy; Treatment Outcome
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11622

Taxane-based chemotherapy is useful for peritoneal dissemination control in advanced/recurrent gastric cancer; however, insufficient relative dose intensity (RDI) may preclude disease control achievement. Nab-paclitaxel, with high tumour permeability, is a promising second- or later-line treatment. We retrospectively evaluated the clinical safety and efficacy of nab-paclitaxel for advanced/recurrent gastric cancer patients treated between April 2013 and December 2015. The response rate, RDI and survival outcomes were assessed. Of 14 evaluated patients, 4 achieved partial response. Overall response and the disease control rates were 28.5% and 64.2%, respectively. Nine patients developed peritoneal metastasis; their overall response and disease control rate were 22.2% and 66.6%. Patients with high RDI (≥80%) showed longer progression-free and overall survival than those with low RDI (≤80%) (11.8 vs. 4.0 months, p=0.02; and 14.3 vs. 8.2 months, p=0.03, respectively). Nab-paclitaxel, at an RDI ≥80%, was safe and beneficial for these patients.